Transcriptomics

Dataset Information

0

Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation


ABSTRACT: One of the primary mechanisms of tumor cell immune evasion is the loss of antigenicity, which arises due to lack of immunogenic tumor antigens as well as dysregulation of the antigen processing machinery. In a screen for small-molecule compounds from herbal medicine thatpotetiate T cell-mediated cytotoxicity, we identified atractylenolide I (ATT-I) that significantly promotes tumor antigen presentation of both human and mouse colorectal cancer (CRC) cells and thereby enhances the cytotoxic response of CD8+ T cells. Cellular thermal shift assay (CETSA) with multiplexed quantitative mass spectrometry identified the proteasome 26S subunit non-ATPase 4 (PSMD4), an essential component of the immunoproteasome complex,as a primary target protein of ATT-I. Binding of ATT-I with PSMD4 augments the antigenprocessing activity of immunoproteasome, leading to enhanced major histocompatibility class I(MHC-I)-mediated antigen presentation on cancer cells. In syngeneic mouse CRC models and human patient-derived CRC organoid models, ATT-I treatment promotes the cytotoxicity of CD8+ T cells and thus profoundly enhances the efficacy of immune checkpoint blockade therapy. Collectively, we show here that targeting the function of immunoproteasome with ATT-I promotes tumor antigen presentation, empowers T-cell cytotoxicity, and thus elevates the tumorresponse to immunotherapy.

ORGANISM(S): Mus musculus

PROVIDER: GSE171158 | GEO | 2021/03/31

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2024-05-16 | GSE227998 | GEO
2020-01-23 | GSE144099 | GEO
2022-03-03 | PXD029507 | Pride
| PRJNA1048747 | ENA
2023-03-04 | E-MTAB-10745 | biostudies-arrayexpress
2023-03-13 | PXD039805 | Pride
2022-10-19 | GSE186203 | GEO
2024-05-31 | GSE239426 | GEO
2024-05-31 | GSE239423 | GEO
2024-05-31 | GSE256058 | GEO